AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04478812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single Group Assignment
Description: Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
Study NCT05291611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-based Cognitive-behavioral Therapy for OCD
Description: 26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
Study NCT05798455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Pentaborate
Description: Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
Study NCT04576078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral nefopam
Description: Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
Study NCT04576078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
Study NCT06358586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachipirina® 120 mg/5 mL oral suspension, new flavour
Description: A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
Study NCT05250999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
Study NCT04156984 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab Prefilled Syringe
Description: See arm description
Study NCT04803734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate inhalation aerosol 108mcg per actuation
Description: MDI, 2 puffs, single dose, fasting
Study NCT04803734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation
Description: MDI, 2 puffs, single dose, fasting
Study NCT05354921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling Catheter
Description: Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
Study NCT05354921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Catheterization
Description: Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR>400 mL, an intermittent catheter will be used. If PVR> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time.
Study NCT05911061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Description: boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Study NCT05911061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Description: boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Study NCT05911061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
Study NCT05911061 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: saline
Study NCT05565079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenerative tissue matrix and enamel matrix derivative
Description: Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
Study NCT05565079 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative tissue matrix
Description: Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
Study NCT05816707 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture
Study NCT05565079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenerative tissue matrix
Description: Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
Study NCT06322602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial Catheter Placement
Description: Undergo Ommaya reservoir placement
Study NCT06322602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP
Study NCT06322602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06322602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF sample collection
Study NCT05816707 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma Longa gel
Description: Curcuma Longa gel
Study NCT05816707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: extraction socket
Description: extraction socket
Study NCT05816707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extraction socket
Description: extraction socket
Study NCT06398054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg tablet
Study NCT06398054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg tablet
Study NCT06322602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06398054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine N-Butil Bromide
Description: Hyoscine N-Butil Bromide 10 mg two tablets
Study NCT06398054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two tablets
Study NCT06265259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of vasopressine as a first vasoconstrictive drug
Description: The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
Study NCT06265259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of noradrenaline as a first vasoconstrictive drug
Description: ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
Study NCT05195801 — intervention group
Intervention type: DEVICE
Intervention: USG
Description: Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
Study NCT05721833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory
Description: Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
Study NCT05721833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Bilevel Positive Pressure Ventilation
Description: Noninvasive Bilevel Positive Pressure Ventilation.
Study NCT04608786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 5mg/kg
Description: ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
Study NCT04608786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
Study NCT05383560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 Vaccine
Description: Omicron Variant-Matched Vaccine
Study NCT05383560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MRNA-1273 Vaccine
Description: Moderna's commercial COVID-19 Vaccine
Study NCT05383560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal Saline for injection
Study NCT05383560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline for injection
Study NCT05918549 — intervention group
Intervention type: DEVICE
Intervention: Motion Analysis in Musculoskeletal Oncology
Description: Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
Study NCT04753697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Subcutaneous
Study NCT05585398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Intradermal injections using different delivery methods (conventional needle and microneedles)
Study NCT05567679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazverik
Description: Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
Study NCT05383560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MRNA-1273.222 Vaccine
Description: Moderna's commercial COVID-19 Vaccine
Study NCT04753697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous
Study NCT04753697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study NCT05749354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.
Study NCT05749354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.
Study NCT05749354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.
Study NCT05988190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextual Word Learning Intervention
Description: Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
Study NCT05570890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical noise stimulation
Description: The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
Study NCT05570890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Participants will not receive stimulation.
Study NCT05570890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam
Description: The foam will be used to make an unstable surface.
Study NCT06551714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase 1 cardiac rehabilitation
Description: Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given.
Study NCT06551714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 cardiac rehabilitation
Description: Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given.
Study NCT06551714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurophysiological facilitation techniques
Description: In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days.
Study NCT04684472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified anti-CD19 CAR T cells
Description: intravenous infusion
Study NCT05385549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
Study NCT05840107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
Study NCT06488339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and oil supplement
Description: Take 1 sachet/day replaced dinner
Study NCT05810428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GKRS-VR training
Description: One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
Study NCT05810428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
Study NCT05593497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
Study NCT05593497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib.